Passage Bio Inc
PASG
查看详细走势图
9.590USD
+0.150+1.59%
收盘 12/19, 16:00（美东）报价延迟15分钟
30.48M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.59%
5天
-2.09%
1月
+28.90%
6月
+22.63%
今年开始到现在
-15.45%
1年
-27.35%
查看详细走势图
TradingKey Passage Bio Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Passage Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
39.600
目标均价
+299.19%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Passage Bio Inc亮点
亮点风险
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
估值高估
公司最新PE估值-0.04，处于3年历史高位
机构减仓
最新机构持股1.76M股，环比减少26.22%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值70.82K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.92
Passage Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Passage Bio Inc简介
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
公司代码PASG
公司Passage Bio Inc
CEOChou (William)
网址https://www.passagebio.com/
常见问题
Passage Bio Inc(PASG)的当前股价是多少？
Passage Bio Inc(PASG)的当前股价是 9.590。
Passage Bio Inc的股票代码是什么？
Passage Bio Inc的股票代码是PASG。
Passage Bio Inc股票的52周最高点是多少？
Passage Bio Inc股票的52周最高点是20.200。
Passage Bio Inc股票的52周最低点是多少？
Passage Bio Inc股票的52周最低点是5.124。
Passage Bio Inc的市值是多少？
Passage Bio Inc的市值是30.48M。
Passage Bio Inc的净利润是多少？
Passage Bio Inc的净利润为-64.77M。
现在Passage Bio Inc(PASG)的股票是买入、持有还是卖出？
根据分析师评级，Passage Bio Inc(PASG)的总体评级为买入，目标价格为39.600。
Passage Bio Inc(PASG)股票的每股收益（EPS TTM）是多少
Passage Bio Inc(PASG)股票的每股收益（EPS TTM）是-14.337。
相关品种
